Cosmo NVCMOPF -3.22%82 Altman Z2-Score is 7.46 as of Jun. 28, 2026, which is 5% above its 10-year median of 7.10. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $53.54 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 994 Drug Manufacturers companies, Cosmo NV ranks better than 76.16% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Cosmo NV has a Altman Z2-Score of 7.46, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Cosmo NV's Altman Z2-Score or its related term are showing as below:
CMOPF'
s Altman Z2-Score Range Over the Past 10 Years
Min: 3.97 Med: 7.1 Max: 21.72
Current: 7.46
During the past 13 years, Cosmo NV's highest Altman Z2-Score was 21.72. The lowest was 3.97. And the median was 7.10.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Cosmo NV Altman Z2-Score Related Terms
Cosmo NV Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMOPF vs LLY, JNJ, ABBV: Altman Z2-Score Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Altman Z2-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Cosmo NV's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.2575
+
3.26
*
0.516
+
6.72
*
-0.0013
+
1.05
*
3.9066
=
7.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Cosmo NV (CMOPF) has a Altman Z2-Score of 7.46 as of Jun. 28, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Cosmo NV and its competitors. This is near median its historical median of 7.10. Over the past decade, Cosmo NV's Altman Z2-Score has ranged from 3.97 to 21.72. According to the industry distribution chart, Cosmo NV ranks #237 out of 994 companies in the Drug Manufacturers industry, placing it in the top 23.8%.
Is Cosmo NV's Altman Z2-Score too high?
Cosmo NV's current Altman Z2-Score of 7.46 is near median its 10-year median of 7.10. Over the past 10 years, this metric has ranged from a low of 3.97 to a high of 21.72. The Drug Manufacturers industry median Altman Z2-Score is 3.87. Cosmo NV's value of 7.46 is 93% above this industry median. Based on the distribution chart, Cosmo NV ranks #237 out of 994 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Altman Z2-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #237 out of 994 companies for Altman Z2-Score. This places Cosmo NV in the top 24% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.87. Cosmo NV's value of 7.46 is 93% above this benchmark. Historically, Cosmo NV's own Altman Z2-Score has ranged from 3.97 to 21.72 over the past decade. While the company's 10-year median is 7.10 vs. the industry median of 3.87, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Altman Z2-Score of 7.46 is 93% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Altman Z2-Score is 7.46, which is near median its own 10-year median of 7.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.54, compared to a current price of $82.00 — trading 53.2% above its estimated fair value. The current Altman Z2-Score is 7.46, which is near median its 10-year median of 7.10 and 93% above the Drug Manufacturers industry median of 3.87. Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Altman Z2-Score is 7.46 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $82.00 is trading 53.2% above its estimated GF Value™ of $53.54.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
Altman Z2-Score: 7.46 (near median its 10-year median of 7.10)
GF Value™: $53.54 vs. price of $82.00 (53.2% above fair value)
Industry Position: 93% above the Drug Manufacturers median (#237 of 994)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score
Get the complete analysis for CMOPF
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
